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The major objective of this study was to investigate the effect of biodegradable polymer type and 
surfactant concentration on various characteristics viz. particle size, entrapment efficiency and drug 
release rate constant of aqueous core nanocapsules (ACNs) containing tenofovirdisoproxil fumarate. In 
this study, the nanocapsules were prepared by modified multiple emulsion technique with biodegradable 
polymers viz. poly(lactide-co-glycolide) of two different grades (PLGA RG502H and PLGA RG503H) 
and poly lactic acid (PLA R203H); and the surfactant employed was span 80. The experiments were 
designed under response surface methodology by employing the Design Expert software. Entrapment 
efficiency, particle size and drug release rate constant were taken as response variables. The prepared 
nanocapsules were subjected to characterization studies and the obtained results were statistically analyzed 
by Analysis of Variance (ANOVA) for response surface 2-Factorial Interaction model. ANOVA studies 
showed that the influence of both factors on all the response variables were significant at p<0.05. The 
optimized formulation was found to have the entrapment efficiency of 71.58%, particle size of 252.41 
nm and the drug release rate constant of 0.045 h-1; thus, indicating that the ACNs were obtained with 
finest characteristics. SEM studies showed that the particles were spherical.
Keywords: Aqueous core nanocapsules. Type of polymer. Surfactant concentration. Response surface 
methodology.
INTRODUCTION
Carrier mediated drug delivery systems have 
received a growing significant interest in the recent years 
due to its ability of being utilized as carriers for the drug 
delivery for various causes such as targeted delivery (Li et 
al., 2008), improving bioavailability (Jia, 2005), crossing 
blood brain barrier (Dufes, 2011) and overcoming the 
inhibitory actions of glycoprotein-P (P-gP) for permeation 
of drugs into the cells (Brigger, Dubernet, Couvreur, 
2002). Furthermore, due to the stability and suitability 
of incorporating wide variety of drugs,the biological, 
polymeric nanoparticles have gained a major share of 
attention among various nanocarriers viz. liposomes, 
niosomesand solid lipid nanoparticles (Baratt, 2000). 
Nanoparticles can be manufactured from a wide variety 
of natural and synthetic polymers which may or may not 
be biodegradable. The use of biodegradable polymers is 
advantageous because they are not deposited in the body 
and pose no toxicity risk, as they degrade into soluble and 
easily excretable form. These biodegradable polymeric 
nanoparticles can be effectively given through intravenous 
route in order to control the spatial and temporal delivery 
of the incorporated drugs. Due to their submicron size 
and wide possibility of modifying their surface, these 
can be employed to deliver drugs at varied target sites 
(Doppalapudi et al., 2016).
Poly (lactide-co-glycolide) (PLGA) and poly 
lactic acid (PLA) are the most used among various 
biodegradable polymers because their hydrolysis results 
into the simple monomers viz. lactic acid and glycolic 
acid which are endogenous to the body and hence have 
little or no toxicity. PLGA and PLA polymers can be 
obtained to have carboxylic acid functions as end groups 
so that these can have higher negative zeta potential iD
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(Nicolete, Santos, Faccioli, 2011; Maharana, Mohanty, 
Negi, 2010). Nanoparticles prepared with these polymers 
can have high negative zeta potential such that they can 
be readily engulfed by macrophages and deliver them into 
the reticuloendothelial system rich organs like spleen and 
liver (Honary, Zahir, 2013). Hence, nanoparticles prepared 
with polymers can be used as passive targeting carriers 
for delivering drugs into the liver in cases of the drugs 
used to treat diseases like hepatitis B. Tenofovirdisoproxil 
fumarate (TDF) is a prodrug that converts intracellularly 
into tenofovir monophosphate and tenofovirdiphospahte. 
It is an antiviral drug used in the treatment of HIV and 
chronic hepatitis B. It has a poor bioavailability of 25% 
after oral administration. TDF is a substrate for P-gP and 
breast cancer resistance protein (BCRP) which efflux 
transporters that limit its availability inside the cells 
(Neumanova et al., 2014). These drawbacks make TDF a 
most desirable candidate to be developed into polymeric 
nanoparticulate systems which improve the bioavailability 
as well as avoid the effects of P-gP and BCRP.
Polymeric nanoparticles are prepared by various 
techniques such as nanoprecipitation, emulsion solvent 
evaporation, salting-out, polymerization etc. (Rao, 
Geckeler, 2011). Moreover, the encapsulation efficiency 
of these methods in case of water soluble drugs like TDF 
is always a concern, as these drugs tend to leach out 
easily. Aqueous core nanocapsules (ACNs) is one of the 
few techniques reported to improve the encapsulation 
efficiency of these drugs (Vrignaud et al., 2013). High 
encapsulation efficiency of ACNs is due to their unique 
liquid core which is optimized to have high solubility 
for the hydrophilic drugs and require less amount of 
polymer in comparison with polymer nanospheres. In 
vivo performance of the nanoparticles largely depends 
on major physicochemical characteristics like particle 
size, zeta potential, drug content and drug release rate 
constant (Crucho, Barros, 2017). Hence, it is important 
to investigate the influence of formulation and process 
variables on these characteristics of nanoparticles in 
order to improve their in vivo performance. Extensive 
literature studies revealed that numerous studies 
have been reported in this regard covering mainly 
the influence of polymer concentration, nature and 
composition of solvents, temperature, speed of rotation 
etc. But, only very few studies were reported regarding 
the influence of type of polymer, molecular weight of 
polymer and surfactant concentration on performance 
of nanoparticles. Budhian, Siegel and Winey (2005) 
studied the influence of ratio of lactic acid to glycolic 
acid in PLGA polymer. Sharma, Madan and Lin (2016) 
studied the effect of co-surfactant on the characteristics 
of nanoparticles. So, there is a large scope in studying 
the influence of these formulation parameters in order 
to add new data to the already existing data that might 
result in the development of nanoparticles with improved 
performance. Therefore, in this study, we aimed to 
prepare ACNs of TDF by modified multiple emulsion 
technique and explore the influence of type of polymer, 
molecular weight of polymer and the concentration 
of surfactant in the primary emulsion on entrapment 
efficiency, particle size and drug release rate constant. 
In this study, the polymers taken were PLGA of two 
different molecular weight grades viz. PLGA RG502H 
and PLGA RG503H, and PLA R203H; and the surfactant 
taken was span-80. The experiments for this purpose 
were designed according to response surface one factorial 
design that was repeated for every categorical factor and 
the obtained results were statistically analyzed using Stat 
Ease Design Expert software.
MATERIAL AND METHODS
Materials
TDF was obtained from Hetero Drugs Ltd 
(Hyderabad, India). Poly (D,L lactic acid) (RESOMER 
R203H/PLA R203H) and Poly (D,L lactide-co-glycolide) 
(RESOMER RG503H/ PLGA RG503H and RESOMER 
RG502H/PLGA RG502H) were obtained from Sigma-
Aldrich (Mumbai, India). Poly vinyl alcohol was obtained 
from MecrkSpecialitiesPvt Ltd (Mumbai, India). Pluronic 
F-68, Span 80 and Chloroform were obtained from S.D 
Fine Chemicals (Mumbai, India). All other chemicals used 
were of reagent grade. 
Methods
Fourier transform infrared spectroscopy
The physicochemical compatibility of TDF with 
PLA R203H, PLGA RG503H and PLGA RG502H 
used in this work were carried out by subjecting it to 
IR spectral studies using Fourier Transform Infrared 
(FT-IR) Spectrophotometer. The samples were prepared 
by mixing the 100 mg of TDF with 100 mg of each 
polymer and prepared as pellets with KBr using the 
hydraulic press. These pellets were scanned under diffuse 
reflectance mode and spectra were recorded in wave 
length region between 4000 cm-1 to 400 cm-1. Every 
spectrum was taken as mean of 16 scans per sample 
(Mohamed et al., 2017). The obtained spectrum of pure 
drug was compared with those of the physical mixtures 
of the drug and polymers.
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Preparation of TDF Aqueous Core Nanocapsules 
(TDF-ACNs)
• Experimental design
In this study, the concentration of surfactant in 
primary emulsion (w/o) and type of polymer were taken 
as two factors. Here, concentration of span 80 was the 
only numeric factor as the type of polymer is a categorical 
factor. So, a one factorial design was considered for 
the experiment. A linear model with three levels of the 
numeric factor (A, surfactant in primary emulsion – 0%, 
0.25% and 0.5% v/v) was considered and this design was 
repeated for every combination with categorical factor (B), 
which is also at three levels i.e. three types of polymers 
viz. PLGA RG503H, PLGA RG502H and PLA R203H. 
The experimental runs including combinations of factors 
at various levels were given in Table I. The response 
variables selected were entrapment efficiency, particle size 
and drug release rate constant.
• Preparation of TDF-ACNs
Nanocapsules of TDF were prepared by multiple 
emulsification method, which resulted after making 
modifications to the method reported by Yadav and 
Sawant (2010). A total of 100 mg of TDF was dissolved 
in 5 mL of aqueous phase consisting of distilled water 
and co-solvent (Methanol) in the ratio of 4:1 with 1% 
polyvinyl alcohol as stabilizer. Approximately 100 mg of 
polymer was dissolved in 10 mL of chloroform containing 
span80 at a concentration of 0.0%/ 0.25%/0.5% v/v, 
respectively. The aqueous phase was then added in drops 
to the organic phase while r stirring at 12,000 rpm for 
30 min to form primary emulsion of w/o type. Thereafter, 
the above primary emulsion was added drop wise to 
20 mL of 50 %v/v aqueous glycerol as external phase 
containing 0.4% v/v of Pluronic F-68 under continuous 
stirring until the chloroform was evaporated. The 
obtained suspension of nanocapsules was stored in the 
refrigerator. Nanocapsules were then recovered from the 
nanodispersion by centrifugation (Thermo Scientific) for 
30 min at 8,000 rpm and 4 °C, washed two times with 
distilled water to remove unentrapped drug and the pellet 
was collected. The supernatant was then used to estimate 
the unentrapped drug so as to determine the entrapment 
efficiency. The dispersion was finally lyophilized for 24h 
to yield freeze-dried nanocapsules which were stored in 
air tight containers until further use.
Characterization of TDF-ACNs
Differential Scanning Calorimetry (DSC)
The physical state of TDF and polymers PLGA 
RG503H and PLA R203H inside the prepared nanocapsules 
were characterized by plotting DSC thermographs 
TABLE I - Combinations of the selected factors according to the design and the obtained results of TDF-ACNs
S. No. Formulation code
Run 
order
Concentration 
of span 80 
(%v/v)
Type of polymer
Entrapment 
efficiency 
(%)
Loading 
efficiency 
(%)
Particle 
size 
(nm)
Zeta 
potential 
(mV)
Release 
rate 
constant 
(h-1)
1 F1 1 0 PLGA RG503H 64.08 27.11 274.3 -27.6 0.055
2 F1 R 9 0 PLGA RG503H 65.49 27.70 271.7 -25.8 0.054
3 F2 4 0.25 PLGA RG503H 69.17 29.26 265.3 -26.9 0.051
4 F3 3 0.5 PLGA RG503H 74.25 31.41 258.6 -28.1 0.047
5 F3 R 5 0.5 PLGA RG503H 73.86 31.24 255.1 -29.3 0.046
6 F4 12 0 PLGA RG502H 58.21 24.62 250.6 -23.4 0.085
7 F4 R 15 0 PLGA RG502H 57.49 24.32 249.8 -21.9 0.083
8 F5 10 0.25 PLGA RG502H 66.15 27.98 244.3 -22.7 0.069
9 F6 6 0.5 PLGA RG502H 68.83 29.12 242.5 -24.2 0.057
10 F6 R 11 0.5 PLGA RG502H 70.58 29.86 238.9 -22.8 0.058
11 F7 2 0 PLA R203H 60.13 25.44 271.2 -18.3 0.052
12 F7 R 7 0 PLA R203H 62.27 26.34 269.7 -20.1 0.054
13 F8 14 0.25 PLA R203H 65.96 27.90 258.1 -18.9 0.049
14 F9 8 0.5 PLA R203H 70.35 29.76 249.3 -21.5 0.046
15 F9 R 13 0.5 PLA R203H 71.52 30.25 250.4 -19.5 0.045
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(Mainardes, Gremião, Evangelista, 2006). The sample 
was weighed, crimped into an aluminum pan and analyzed 
at a scanning temperature range from 20 to 250 °C at the 
heating rate of 10 °C/min in nitrogen atmosphere. The 
thermographs of pure TDF, PLGA RG503H and PLA 
R203H were compared with those of TDF nanocapsules 
with PLGA RG503H as well as PLA R203H.
Particle size and zeta potential
The particle size and zeta potential  of the 
prepared TDF-ACNs were determined by dynamic light 
scattering (DLS) technique using ZetaSizer Nano-ZS90 
(Malvern Instruments, UK) (Asasutjaritet al., 2013). 
The measurements were carried out at an equilibrated 
temperature of 25 °C and at a fixed scattering angle of 90°. 
The samples were tolerably diluted with distilled water 
before measurement, and measurements were made in 
triplicate for every sample.
Scanning Electron Microscopy (SEM)
The shape and surface characterization of 
nanocapsules were observed under Scanning Electron 
Microscope (ZEOL JSM–5610). The dispersion of 
nanocapsules was sufficiently diluted and a small drop was 
mounted directly on the SEM sample stub, using double-
sided sticking tape, and coated with gold film (thickness 
200 nm) under reduced pressure (0.001 Torr) and it was 
thereafter photographed.
Entrapment efficiency and drug loading
Colloidal suspension of TDF-ACNs was centrifuged 
for 30 min at 8,000 rpm and 40C. The solid pellet was 
washed twice with water to remove the unentrapped 
drug. Then, the supernatant was collected and subjected 
to analysis by UV-Visible Spectrophotometer at λmax of 
260 nm to determine the amount of drug unentrapped, 
from which the amount of drug entrapped was calculated 
(Soma et al., 2017). The entrapment efficiency and drug 
loading were calculated using the following formula
In vitro drug release studies
In vitro release studies were carried out by 
dialysis bag method using dialysis membrane (Dialysis 
Membrane-110; HiMedia Lab. Pvt. Ltd., Mumbai) (Gupta 
et al., 2013; Bohrey, Chourasiya, Pandey, 2016). The 
TDF-ACNs were suspended in a small quantity of water; 
placed in the Gelatin bag that was sealed at both ends and 
suspended on receptor compartment containing 100 ml 
buffer solution (0.1N HCl) in a beaker. The medium in the 
receptor was agitated continuously using a magnetic stirrer 
at 100 rpm and temperature was maintained at 37±0.5 °C. 
A total of 2mL of samples of receptor compartment were 
taken at various time intervals over a period of 24h and at 
each time, fresh buffer of same volume was added. The 
samples were analyzed spectrophotometrically at 260 nm 
after suitable dilutions to determine the amount of drug 
released.
Drug release kinetics and mechanism
The data obtained from the drug release studies 
were subjected to zero – order and first – order kinetic 
models for determining the drug release kinetics and also 
subjected to Higuchi’s and Korsemeyer – Peppas models 
for identifying the mechanism of drug release.
Design of Experiments validation and ANOVA
The concentration of surfactant was the only numeric 
factor as the type of polymer was a categorical factor. So, 
one factorial design linear model with one center point 
under response surface methodology was selected as the 
model which was repeated for all the three categorical 
factors, these resulted in a total of 15 runs. The TDF-ACNs 
for the 15 runs were prepared and characterized. Obtained 
results of the response variables were analyzed by 
response surface polynomial 2-Factorial Interaction (2FI) 
model without need of any transformation. The design was 
validated for its suitability into the selected 2FI model 
by plot of predicted versus actual results of the response 
variables; and also by the ANOVA of classical sum of 
squares – Type III 2FI model.
RESULTS AND DISCUSSION
FT – IR Studies
Compatibility studies of drug and polymer were 
conducted by employing I.R spectral studies. IR spectra 
of pure Tenofovir DF and the physical mixtures of drug 
and polymers were showed in Figure 1. The bands 
for characteristic groups of the pure Tenofovir DF 
were observed at 1622.93 cm-1 due to N-H bending; 
1675.44 cm-1 due to stretching of imine (R2-C=NR1) 
group; 1263.23 cm-1 because of theprimary aromatic 
amine stretching; 1755.23 cm-1 due to carbonyl (C=O) 
stretching; 1184.24 cm-1 due to P=O stretching and at 
Study on influence of polymer and surfactant on in vitro performance of biodegradable aqueous-core nanocapsules
Braz. J. Pharm. Sci. 2019;55:e18736 Page 5 / 11
3223.48 cm-1 accounting for O-H stretching (Gomes et 
al., 2015; Silverstein, Webster, Kiemle, 2005). These 
bands accounting for the characteristic groups of TDF 
were also observed at the similar positions in the spectra 
of individual physical mixtures of TDF with the polymers 
viz. PLGA RG503H, PLGA RG502H and PLA R203H. 
These results showed that there was no interaction between 
TDF and the polymers as the characteristic bands were 
observed at the identical positions in the spectrum of pure 
drug and also in the spectra of physical mixtures.
Preparation of TDF-ACNs
TDF-ACNs were prepared through W/O/W 
emulsion by modified multiple emulsification method. 
The aqueous solution of TDF was emulsified in the 
chloroform solution of polymer to get W/O emulsion. 
When this emulsion was further dispersed in aqueous 
phase to get W/O/W emulsion and subjected to continuous 
stirring, chloroform got evaporated leaving the polymer 
to deposit on the internal aqueous phase globules. Once 
the chloroform got removed completely, the polymer was 
rigidized leaving discrete nano-sized particles with small 
aqueous droplets containing the drug as core and the 
rigid polymer as coat, so that they were called Aqueous 
Core Nanocapsules. The SEM studies indicated that the 
obtained nanocapsules were almost spherical in shape 
as shown in Figure 2. Here, two surfactants span 80 and 
Pluronic F-68 were taken as emulsion stabilizers in the 
primary and secondary emulsions respectively. All the 
selected polymers in this study viz. PLGA RG503H, 
PLGA RG502H and PLA R203H were predominantly 
hydrophobic (Kohn, Langer, 2004; Hines, Kaplan, 
2013),such that the nanocapsules obtained from these 
polymers have relatively hydrophobic surface which 
make them attacked by opsonins, that leads them to be 
phagocitized easily by Reticuloendothelial system (RES) 
rich organs, such as liver and spleen. Nanocapsules with 
these characteristics are better for passive targeting of 
drugs into liver in the treatment of liver diseases like TDF 
and for the treatment of hepatitis B. 
Experimental design
In this work, one numeric (surfactant concentration, 
A) and one categorical (type of polymer, B) factor were 
taken, so a one factorial design repeated for every categoric 
factor was employed. Experiments were done according 
to the combinations of the factor levels suggested by 
the software. The obtained results were analyzed by 
polynomial 2FI model. The equations for the responses 
were obtained as
Final Equation in Terms of Coded Factors:
EE = +66.56 + 5.14*A + 2.81*B[1] - 2.30*B[2] - 
0.51*AB[1] + 0.78*AB[2]
FIGURE 1 - FT – IR spectra of (a) Pure TDF; (b) Physical mixture of TDF and PLGA RG503H; (c) Physical mixture of TDF and 
PLGA RG502H; (d) Physical mixture of TDF and PLA R203H
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Particle size = +256.65 - 7.71*A + 8.35*B[1] - 11.43*B[2] 
- 0.37*AB[1] + 2.96*AB[2]
k = +0.057 – 0.007*A – 0.006*B[1] + 0.014*B[2] + 
0.003*AB[1] – 0.006*AB[2]
where, EE = Entrapment efficiency; k = drug release rate 
constant; A = surfactant concentration; B[1] and B[2] are 
coefficients of multi-level categorical factor.
Differential Scanning Calorimetry (DSC)
DSC analysis was performed to investigate the 
physical state of drug in the prepared ACNs. For this 
purpose, DSC spectra were taken for pure TDF; pure 
polymers PLA R203H and PLGA RG503H; ACNs of 
TDF with PLA as well as with PLGA. The spectra were 
shown in Figure 3. The spectra of pure drug showed a 
sharp endothermic peak at 118.1 °C corresponding to its 
melting point temperature which is around 115 °C. But this 
endothermic peak was found to be absent in the spectra of 
TDF ACNs with either of the polymers, which indicated 
that the drug was in no more crystalline state in the ACNs, 
instead it might be in either molecular dispersion or 
amorphous form (Shailender et al., 2017). This might be 
attributed to the mode of incorporation of drug i.e. in its 
aqueous solution form into the nanocapsules during their 
preparation.
In case of the polymer PLA R203H, its pure spectra 
showed an endothermic peak at 55.4 °C corresponding to 
its glass transition temperature (Tg).Then, an exothermic 
peak at 104.8 °C which corresponds to the re-crystallization 
of PLA and this was followed by another endothermic peak 
at 156.3 °C, which indicated melting of the PLA (Tabi et 
al., 2010). In the spectra of TDF ACNs with PLA, the Tg of 
PLA was increased and observed at 59.3 °C which might 
be because of its rapid solidification during the process. 
The absence of further peaks of re-crystallization and its 
melting might be attributed to the solidification of PLA 
into amorphous form. The increase in Tg was also found 
in case of PLGA as the endotherm in its pure spectra was 
observed at 48.1 °C and in the spectra of ACNs with PLGA 
at 51.2 °C (Yang et al., 2016).
FIGURE 2 - SEM images of TDF-ACNs prepared with PLGA RG503H of formulation F3.
FIGURE 3 - DSC spectra of  (a) Pure TDF; (b) Pure PLA 
R203H; (c) TDF-PLA R203H ACNs; (d) Pure PLGA RG503H; 
(e) TDF-PLGA RG503H ACNs.
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Particle size
TDF-ACNs in the size range of 242.5 to 274.3 nm 
were obtained (refer to Table I). Influence of the factors 
are shown in Figure 4(a). The particle size was found to 
decrease upon increase in the surfactant concentration. 
This might be attributed to the ability of surfactant to 
reduce the interfacial tension and hence the interfacial 
free energy, so that higher amount of surfactant results to 
an emulsion with high interfacial area, that means smaller 
particle size with good stability (Sinko, 2017). The results 
were in agreement with those reported by Rehfeld in case 
of benzene-in-water emulsions (Rehfeld, 1967); and also 
with those reported by Gupta et al.(2015) in case of solid 
lipid nanoparticles (Gupta et al., 2015). The particle size 
was found to be influenced by the type of polymer as 
bigger size particles were observed with PLGA RG503H 
followed by PLA R203H and smaller size particles were 
observed with PLGA RG502H. This might be attributed 
to the molecular weight of the polymers. The molecular 
weights of PLGA RG503H, PLGA RG502H and PLA 
R203H are 24000 – 38000; 7000-17000 and 18000 – 
28000, respectively. The viscosity of the polymeric 
solution is directly proportional to its molecular weight. 
Under similar experimental conditions, a low viscosity 
polymer solution could better be dispersed in external 
aqueous medium with fine globule size than could a high 
viscous polymer solution, such that the size was reduced 
in the case of PLGA RG502H and increased in the order 
of increasing molecular weight (Ravi et al, 2008). The 
differences in particle size of formulations with different 
concentrations of surfactants and different polymers 
was statistically significant at p<0.05 (as shown in 
Table II).
Zeta potential
The zeta potential values of prepared TDF-ACNs 
were found to be in the range of -18.3 to -27.6 mV as 
shown in Table I. The average zeta potential of TDF-
ACNs was found to be -27.54 mV in the case of PLGA 
RG503H; -23.00 mV in the case of PLGA RG502H; 
and -19.66 mV in the case of PLA R203H. The negative 
zeta potentials were attributed to the presence of free 
carboxylic acid as end groups on all the three selected 
polymers (Nicolete, dos Santos, Faccioli, 2011; 
Maharana, Mohanty, Negi, 2010). These results indicated 
that there was no influence of concentration of surfactant, 
but the type of polymer had influence as the zeta potential 
might be solely dependent on the nature of polymer that 
forms the mantle of the nanocapsules. The high negative 
zeta potential was also responsible for good physical 
stability in suspension form.
Entrapment efficiency
The entrapment efficiency of TDF-ACNs was found 
to be in the range of 58.21 – 73.86% (refer to Table I). 
Influence of the factors in this stage on entrapment 
efficiency areshown in Figure 4(b). The entrapment 
efficiency was found to be more in nanocapsules made 
of PLGA RG503H and decreased in the order of PLA 
R203H and PLGA RG502H. These results indicated 
that the entrapment efficiency was directly proportional 
to the molecular weight of the polymer. The polymer 
with high molecular weight would have restricted the 
escape of the drug encapsulated in it because of its 
high viscosity, resulting in high entrapment efficiency 
(Krishnamachari, Madan, Lin, 2007). The less particle 
FIGURE 4 - Interaction plots showing the influence of surfactant concentration in primary emulsion and type of polymer on (a) 
particle size; (b) entrapment efficiency; (c) drug release rate constant.
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size in case of low molecular weight polymer would 
also be responsible for low entrapment efficiency, as the 
small particles could have high surface area to give more 
opportunity for drug escape from the nanocapsules (Yeo, 
Park, 2004). Hydrophobicity of the polymer can also 
influence the entrapment efficiency,such that the higher 
the hydrophobicity of polymer, the greater the resistance 
for escape of encapsulated drug into the outer aqueous 
medium. An interesting finding was observed in this 
work that though PLA is more hydrophobic than PLGA, 
high entrapment efficiency in case of PLGA RG503H 
demonstrated that the effect of molecular weight of the 
polymer might dominate the effect of hydrophobicity. 
The amount of Span 80, a hydrophobic surfactant, in the 
primary emulsion (W/O) also influenced the entrapment 
efficiency, such that the increase in the concentration of 
Span 80 led to an increase in entrapment efficiency. As 
the Span 80 was employed in primary emulsion (W/O), 
it could be deposited over the surface of the aqueous 
globules along with the polymer. So, upon increase in 
the concentration of Span 80, the nanocapsules became 
more hydrophobic such that the leakage of TDF into the 
outer aqueous medium would be minimized, resulting in 
increased entrapment efficiency. The influence of all the 
factors on entrapment efficiency was significant at p < 0.05 
(as shown in Table II).
The maximum entrapment efficiency observed 
was 73.86%. Few studies have been reported on the 
improvement of entrapment efficiency of hydrophilic 
drugs .  Dordelmann et  a l . (2014)  repor ted  tha t 
encapsulation efficiency of nucleic acids into poly(D,L-
lactide-co-glycolide acid) (PLGA) nanocapsules 
prepared by W/O/W emulsion solvent evaporation 
technique was improved upto 52% by employing calcium 
phosphate in the primary inner phase (Dordelmann et 
al., 2014). Kashi et al. worked on solid/oil/water ion 
pairing method to encapsulate minocycline into PLGA 
nanoparticles and reported a maximum entrapment 
efficiency of 29.9% (Kashi et al., 2012). Peltonen et al 
reported an increase in entrapment efficiency of sodium 
chromoglycate into polylactide nanoparticles upto 70% 
by modified nanoprecipitation method (Peltonen et al., 
2004). Hence, it was inferred that ACNs prepared in this 
study by modified multiple emulsion technique was an 
alternative to improving the entrapment of hydrophilic 
drugs into nanoparticles.
TABLE II - Results of ANOVA for response surface 2-factorial interaction model for the responses
S. No. Response Source SSa Dfb MSSc F value p-Value Inferenced
1 Particle size 
(nm)
Model 1825.01 5 365.00 145.56 <0.0001 Significant
Ae 713.02 1 713.02 284.36 <0.0001 Significant
Bf 1049.58 2 524.79 209.29 <0.0001 Significant
AB 62.41 2 31.21 12.44 0.0026 Significant
Residual 22.57 9 2.51
Lack of Fit 4.53 3 1.51 0.50 0.6943 Not significant
2 EEg (%)
Model 388.68 5 77.74 67.13 <0.0001 Significant
A 317.47 1 317.47 274.15 <0.0001 Significant
B 67.43 2 33.71 29.11 0.0001 Significant
AB 3.78 2 1.89 1.63 0.2482 Not significant
Residual 10.42 9 1.16
Lack of Fit 4.56 3 1.52 1.56 0.2941 Not significant
3 kh (h-1)
Model 2.23x10-3 5 4.46x10-4 461.01 <0.0001 Significant
A 5.88x10-4 1 5.88x10-4 608.28 <0.0001 Significant
B 1.41x10-3 2 7.03x10-4 727.10 <0.0001 Significant
AB 2.34x10-4 2 1.17x10-4 121.29 <0.0001 Significant
Residual 8.70x10-6 9 9.67x10-7
Lack of Fit 2.70x10-6 3 9.00x10-7 0.900 0.4941 Not significant
Note: a Sum of Squares; b Degrees of Freedom; c Mean Sum of Squares; d p-Value less than 0.05 indicates model terms are 
significant; e Polymer concentration (%w/w); e Surfactant concentration (%v/v); f Type of polymer; g Entrapment Efficiency; h 
Release rate constant.
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Drug release studies
The release rate constant of TDF from ACNs was 
found to be in the range of 0.045 – 0.058 h-1 (refer to 
Table I). Influence of both factors on drug release rate 
constant is shown in Figure 4(c). The release rate constant 
from nanocapsules with polymer PLGA RG502H was 
found to be more and this might be because of low 
molecular weight of this polymer among the three. The 
PLA or PLGA with low molecular weight could degrade 
or erode rapidly and release the drug encapsulated in it 
at high rate (Feng et al., 2015). Though, the molecular 
weight of PLA R203H is slightly lower than PLGA 
RG503H, the release rate constant was found to be less 
in TDF-ACNs with the former polymer. This might be 
attributed to the greater hydrophobicity of the PLA that 
could hinder the aqueous medium from having contact 
with the nanocapsules surface, thereby, resulting in 
decreased drug release rate constant (Ravi et al, 2008). 
Upon increase in the amount of Span 80 in the primary 
W/O emulsion, the release rate constant was found to 
be decreased. As the surfactant concentration increased, 
the stability of the emulsion could be increased (Maa, 
Hsu, 1997), which might result in tight adherence of the 
polymer in the outer organic phase onto the surface of the 
internal aqueous phase globules upon evaporation of the 
organic solvent. So, the ACNs with high amount of Span 
80 controlled the release of TDF to a greater extent. The 
influence of both factors on drug release rate constant was 
significant at p < 0.05 (shown in Table II). Drug release 
from all the formulations was found to follow first – order 
kinetics and mechanism of drug release was found to be 
non – Fickian diffusion.
DoE Validation and ANOVA
The plot of predicted versus actual results of the 
response variables were shown in Figure 5. The close 
agreement between the predicted values by the design 
with the actual obtained values from the experiments 
indicated that the selected response surface 2FI model was 
suitable for the design employed in this study. This was 
also further justified by the results of ANOVA (shown in 
Tables II) that the model F value and insignificant lack-of-
fit values in case of each response showed that the model 
was significant and suitable for the design employed in 
this study.
CONCLUSION
The major objective of this work was to study 
the influence of concentration of surfactant in primary 
emulsion and type of polymer on in vitro performance 
of ACNs of TDF that were prepared by multiple 
emulsion technique such that nanocapsules with superior 
characteristics could be developed. The findings of this 
work inferred that type of polymer and concentration of 
surfactant were found to have a significant influence on 
entrapment efficiency, particle size and drug release, such 
that these formulation variables could be successfully 
changed in order to obtain the ACNs with desired 
characteristics. In conclusion, the entrapment efficiency 
of hydrophilic drugs into nanoparticles could be improved 
by the aqueous-core nanocapsules technique.
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